Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged-infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies.
Introduction
b-Lactam antibiotics are routinely prescribed for severe infections in the ICU. As time-dependent antibiotics, the most important pharmacokinetic (PK)/pharmacodynamic (PD) index for their activity is the duration of time over which the unbound (or free) drug concentration remains above the MIC (fT .MIC ). 1 Intermittentbolus (IB) dosing, the standard method of b-lactam administration, commonly produces suboptimal drug concentrations in critically ill patients with conserved renal function. 2 -4 Such patients generally exhibit extreme physiological derangements, which may alter the b-lactam PK and consequently reduce its exposure. 5, 6 Numerous PK/PD simulation studies suggest that optimal b-lactam exposures are readily obtained via continuous infusion or an extended 2-4 h infusion. 2 -4,7 Continuous infusion and extended infusion are jointly referred to as prolonged infusion, with either approach considered to be potentially advantageous compared with traditional IB administration.
Owing to persisting poor sepsis-related clinical outcomes in the ICU, there has been growing concern that conventional antibiotic dosing in critically ill patients is suboptimal. If this notion is true, global antibiotic prescribing practices may need to change accordingly. Aiming to improve antibiotic treatment in the ICU, the Defining Antibiotic Levels in Intensive care unit patients (DALI) study, 8 a large multinational PK point-prevalence study, was undertaken to determine whether conventional dosing of b-lactam antibiotics attains drug concentrations associated with therapeutic benefits in critically ill patients. The implications of the study are profound; 16% of the patients did not achieve the most conservative PK/PD target and these patients were 32% more likely to demonstrate negative clinical outcomes. Although these data led to the conclusion that different dosing strategies are needed in the ICU, they were not discretely analysed to ascertain the potential merits of altered b-lactam infusion in critically ill patients. Of note, with the exception of piperacillin/tazobactam and meropenem, the other six b-lactam antibiotics included in the DALI study were almost exclusively administered by IB dosing, which signifies its 'authority' over prolonged-infusion dosing in current prescribing practices.
Despite compelling pre-clinical and PK/PD data, clinical comparative trials have failed to demonstrate the perceived clinical advantage of prolonged-infusion over IB dosing. 9 Furthermore, most meta-analyses of the clinical trials are still indecisive over the notion of the clinical superiority of prolonged-infusion over IB dosing. 10 -18 There are currently four recent meta-analyses that report significant improvement in clinical cure 10, 11, 13 and survival 10, 11, 15 favouring prolonged-infusion administration. However, their findings should be interpreted with caution as these meta-analyses have included a considerable number of retrospective and non-randomized studies in their pooled analysis. Given the above uncertainty, we utilized the database of the DALI study with the primary aim of distinguishing the relative abilities of prolonged-infusion and IB dosing of piperacillin/tazobactam and meropenem to achieve specific PK/PD exposure targets in relation to the offending pathogen MIC during antibiotic therapy. Secondary aims were to describe clinical response and 30 day survival for both administration approaches and which patient subgroups were most likely to benefit from this intervention.
Methods

Study design
This is a post hoc analysis of the DALI study, for which the detailed study protocol has been described elsewhere. 8, 19 Briefly, during a single dosing interval on the investigation day, each patient had two blood samples drawn for the b-lactams they were receiving (mid-dose and a trough concentration). Various demographic, clinical and treatment-related variables were collected on the day of investigation. CL CR was estimated using the Cockcroft-Gault formula. 20 Patients were included if they received either piperacillin/tazobactam or meropenem, which were administered by prolonged infusion (either continuous or extended infusion) or IB dosing. We followed the inclusion criteria used in previous randomized clinical trials of this intervention, 21 -23 which meant that patients who received any form of extracorporeal renal support were excluded as patients with reduced drug clearances are less likely to benefit from altered administration approaches. 24 -26 For clinical outcome assessment, only patients who received antibiotic for treatment of infection, as opposed to prophylaxis, were included.
The lead site was The University of Queensland, Australia (ethics approval number 201100283). Informed consent was obtained from each eligible patient.
Sample integrity and bioanalysis
Blood samples were processed and stored per protocol prior to shipment to the Burns, Trauma and Critical Care Research Centre, The University of Queensland, Australia, where they were assayed. The details concerning bioanalysis have been described in detail elsewhere. 27 
PK/PD and clinical outcome measures
The primary endpoint, which was PK/PD target attainment, is described in detail in Table 1 . Briefly, to assess the relative dosing adequacy of prolonged-infusion and IB administration, the observed unbound antibiotic concentrations were compared against the causative pathogens actual or 'surrogate' MIC. The secondary endpoints, clinical response and 30 day survival, were assessed using definitions described in Table 1 . Additionally, to investigate clinical differences between prolonged-infusion and IB dosing within the subgroup of patients with the highest illness severity, as described by Lodise et al., 28 we performed a classification and regression tree (CART) analysis to further stratify patients based on SOFA score to identify the patients who were at the greatest risk of clinical failure and 30 day mortality.
Statistical analysis
Data are presented as median values with IQR for continuous variables and number and percentage for categorical variables. A multivariate logistic regression model (manual entry and stepwise, backward elimination) was constructed to identify significant predictors associated with the primary and secondary endpoints, with OR and 95% CI reported. Biologically plausible variables with a P value of ≤0.15 on univariate analysis were considered for model building. However, the administered b-lactam and the method of administration were forced into the regression models regardless of the univariate analysis results. Goodness of fit was assessed using the Hosmer -Lemeshow statistic. A two-sided P value of ,0.05 was considered statistically significant in all analyses. Statistical analysis was performed using IBM SPSS Statistics v22 (IBM Corporation, Armonk, NY, USA).
Results
A total of 211 patients received either piperacillin/tazobactam or meropenem and were considered for study inclusion. Twentynine patients were excluded as they received extracorporeal renal support during ICU stay. The patient inclusion and exclusion process is depicted in Figure 1 and the baseline characteristics of the 182 included patients are presented in Table 2 . For clinical outcome assessment, 37 patients who were only receiving antibiotic prophylaxis were further excluded.
Of the 182 included patients, 110 (60.4%) received piperacillin/ tazobactam. Additionally, 60.4% (110/182) of patients also received Abdul-Aziz et al.
concomitant antibiotic therapy as part of their treatment. The most common administration method was IB; 63.2% (115/182) of the patients received b-lactams via this approach. Among the 67 prolonged-infusion patients, 23 (34.3%) and 44 (65.7%) were continuous-infusion and extended-infusion patients, respectively. Figure 2 illustrates the preferred method of dosing by participating country. Although most countries favoured IB dosing, two countries, Belgium and France, had more than half of the patients receiving the b-lactams by prolonged-infusion dosing. Of 182 patients who received b-lactams, 70 (38.5%) were prescribed them for either presumed or confirmed respiratory infection. Of the patients treated for infection (n¼ 145), 114 (78.6%) had at least one causative pathogen isolated and 40.4% (46/114) of them had actual MIC values for the causative pathogens identified. The numbers of patients with actual MIC data were similar between prolonged-infusion and IB treatment arms [ Table 3 presents the differences in patient characteristics between those who demonstrated positive and negative clinical outcomes in this study. The clinical outcomes were mostly similar between prolonged-infusion and IB patients receiving antibiotics for treatment of infection (Figures 3 and 4 ). However, in the subgroup of patients who had respiratory infection (n ¼ 59), patients receiving b-lactams via prolonged-infusion dosing demonstrated significantly better 30 day survival when compared with IB patients [86.2% (25/29) and 56.7% (17/30), respectively;
Patients who had a SOFA score ≥9 were identified by CART analysis to have the greatest risk of clinical failure [clinical cure rates were 80.0% (88/110) in patients with a SOFA score ,9 versus Bold values indicate statistical significance (P, 0.05). c Represents variable that was included in the multivariate logistic regression model. d PK/PD ratios observed at 50% and 100% of the dosing interval. These indices were defined as the ratio between the unbound plasma concentration (piperacillin/tazobactam or meropenem) at 50% or 100% of the dosing interval and the causative pathogen MIC. Actual MIC values were used when available. Where the MIC was unavailable or no pathogen was formally identified, surrogate MIC values were assumed. 51.4% (18/35) 
Outcome measure predictors
Based on the most parsimonious model, decreasing CL CR values significantly increased the PTA for all PK/PD targets: 50% fT .MIC , OR 0.97, 95% CI 0.98 -0.99, P ¼ 0.007; 50% fT .4×MIC , OR 0.97, 95% CI 0.98 -0.99, P ¼ 0.014; 100% fT .MIC , OR 0.97, 95% CI 0.98 -0.99, P, 0.001; and 100% fT .4×MIC , OR 0.97, 95% CI 0.96 -0.98, P, 0.001. The use of prolonged-infusion dosing, as opposed to IB dosing, significantly increased the PTA for 100% fT .MIC (OR 2.78, 95% CI 1.24 -6.24, P ¼ 0.013).
The results of all multivariate logistic regression models for clinical cure and 30 day survival are available in Table 4 . Based on the most parsimonious logistic regression model, SOFA score (OR 0.89, 95% CI 0.80 -0.99, P ¼ 0.029) and concomitant antibiotic use (OR 0.31, 95% CI 0.10-0.96, P ¼ 0.043) were identified as significant factors associated with clinical cure whilst only SOFA score (OR 0.82, 95% CI 0.73-0.92, P¼ 0.001) was identified as a factor associated with 30 day survival.
Discussion
Altered b-lactam PK is widely reported among ICU patients, potentially leading to suboptimal antibiotic exposures when 'standard' b-lactam dosing is applied in the cohort. 5, 6, 29 In this study, the majority of patients achieved a lower PK/PD target of 50% fT .MIC and the attainment rates were similarly high across the two administration methods and antibiotics. However, clinical data from critically ill patients have suggested that such exposure should be regarded as the minimum, with larger exposures associated with improved outcomes. 30 -33 A more prudent target of 100% fT .MIC should be considered and this was not achieved by one-third of the study patients. Nonetheless, the patients in this cohort were 3-fold more likely to achieve 100% fT .MIC when receiving b-lactams via prolonged-infusion dosing (OR 2.78, 95% CI 1.24 -6.24, P ¼ 0.013). Although such an observation was anticipated, our current work remains unique given that the data were derived from a broad range of ICU environments across 10 countries and the strength of association was established and supported by multivariate regression analyses.
As the b-lactams are predominantly cleared by the kidney, elevated renal function as observed in augmented renal clearance (ARC) may likely lead to suboptimal PK/PD target attainment. 34 -36 In our cohort, increasing values of the estimated CL CR significantly reduced the PTA for all PK/PD indices. Moreover, the observed relationship between CL CR and suboptimal PK/PD exposure was relatively strong in both univariate and multivariate analysis for all PK/PD indices. The probability of attaining 100% fT .MIC would be reduced by 3% with every 1 mL/min increase in the estimated CL CR (OR 0.97, 95% CI 0.98-0.99, P,0.001). The median CL CR of patients who did not attain 100% fT .MIC was 132 mL/min and Prolonged-infusion versus intermittent-bolus dosing of b-lactams 201 JAC only 28.2% (11/39) of those with a CL CR ≥132 mL/min achieved the target. Such patients, who are at risk and usually have apparently 'normal' renal function, need to be identified early so that appropriate dose modification can occur. Young trauma patients (,60 years), without significant organ dysfunction (SOFA ≤4), 37, 38 were more likely to develop ARC and these factors were also evident in our patients who manifested elevated CL CR ; median age was 45 (IQR 35-57) and median SOFA was 4 (IQR 2-7). The significance of illness severity for clinical outcome is also highlighted in this study. In this context, higher SOFA scores were independently associated with greater likelihood of developing clinical failure and death at 30 days after antibiotic sampling. An increase in SOFA score by 1 point reduced the probability of clinical cure and survival by 11.0% and 18.0%, respectively (Table 4 ). Accordingly, we also observed that patients with a SOFA score ≥9 were more likely to demonstrate negative clinical outcomes and, when only these patients were tested, those receiving b-lactams via prolonged-infusion dosing demonstrated significantly better outcomes compared with IB dosing (Figures 3  and 4 ). Higher survival rates favouring prolonged-infusion dosing were also seen in the subgroup of patients with respiratory infection, and our findings further substantiate similar claims of earlier studies that suggested potential benefits of prolonged-infusion administration in severely ill patients with pneumonia. 39 -41 As inappropriate antibiotic treatment has been associated with reduced survival in patients with severe pneumonia, 31, 32, 42, 43 prompt antibiotic administration, with an optimal dosing schedule, is therefore an essential intervention in this population. In this respect, the application of prolonged-infusion dosing could have the merit of enhancing b-lactam penetration into the Abdul-Aziz et al.
interstitial fluid of the infected lung tissues, 26, 44, 45 where the antibiotic -bacteria interactions occur. 46 Furthermore, optimal antibiotic dosing is crucial in this population as it may be directly linked with patient outcomes, 47, 48 whilst for other infection sites, such as intra-abdominal and surgical-site infections, effective source control and the role of the surgeon are probably more crucial in predicting positive outcomes.
However, it is also important to mention that the sample size of patients in these two subgroups was relatively small compared with the number of clinically evaluable patients (,60 versus 145, respectively) and thus the observed statistical significance could have been the result of random chance, although the findings do agree with previous published data. 28 Furthermore, due to the relatively small number of patients in the two subgroups, logistic regression analyses could not be performed and therefore the conclusion that prolonged infusion provided clinical benefits was based on unadjusted analyses, which do not consider the influence of potential confounders. Hence, it is important to highlight that the median pre-ICU days for prolonged-infusion patients in the two subgroups were significantly shorter compared with IB patients (prolonged infusion 2 days, IQR 1 -8; IB 7 days, IQR 2 -12; P ¼ 0.039), and the large difference might skew the results in favour of prolonged infusion. Indeed, our clinical findings provide further evidence that prolonged-infusion dosing of b-lactam antibiotics may not be beneficial for all but rather for a specific subset of critically ill patients with severe infections. Interestingly, no subgroup had worse outcomes with prolonged-infusion dosing, suggesting that widespread use of such an intervention is not likely to have an inferior effect compared with the current standard practice. We believe that this study generates an interesting 'therapeutic' signal, signifying potential clinical superiority of prolonged-infusion dosing in patients with higher SOFA scores and in patients with respiratory infections. Accordingly, future clinical studies should focus on and test the hypotheses of prolongedinfusion dosing benefits specifically in these patient groups. As has been demonstrated by a recent randomized controlled trial, Dulhunty et al. 21 showed that continuous infusion demonstrated better PK/PD and clinical outcomes when compared with IB dosing, and these findings may stem from the strategic approach of only recruiting patients with a higher acuity of illness and in patients not receiving renal replacement therapy.
In this study, concomitant antibiotic therapy reduced the probability of clinical cure by 69.0% (Table 4 ). Although the reasons were unclear, we hypothesize that the more severely ill the patient was, the more likely it was that the patient received multiple antibiotics in an attempt to 'reverse' the impending poor prognosis associated with such patients. Our notion was corroborated by the higher median SOFA score observed in patients who received concomitant antibiotics compared with those who did not (SOFA 6, IQR 3-9, and SOFA 4, IQR 1 -7, respectively; P ¼0.048). Whilst data on concomitant antibiotics were available, we did not specifically evaluate the duration of therapy with these antibiotics and assess their PK/PD, all of which could have confounded the findings in this study.
This study has several limitations that we would like to declare. It is imperative to clarify that in 60% of the patients 'surrogate' MIC values were assumed from population estimates, and such an approach could markedly inflate, or even deflate, the magnitudes of PK/PD target non-attainment observed in this study. In addition, this approach would adversely affect the target attainment rates of IB patients more than those for the prolonged-infusion patients if the surrogate MIC values were indeed higher than the actual MIC values. However, when we employed actual MIC data in our analysis, the findings were consistent with our main approach, where prolonged-infusion patients demonstrated numerically higher target attainment rates, albeit not statistically significantly higher, compared with IB patients across all PK/PD indices. Actual MIC values would have been preferable, although we believe that our present approach closely mimics the real-life clinical approach, in which the MIC for a pathogen is rarely available upon antibiotic treatment initiation. We also acknowledge the limitation of the Cockcroft -Gault formula in estimating the measures of renal function in this cohort, and that measured CL CR would be more appropriate, particularly in patients with ARC. The post hoc nature of this analysis also limits our ability to establish a causal relationship between the methods of b-lactam administration and clinical outcomes. As the antibiotic dosing regimen and all subsequent patient management were at the discretion of the treating physician, this might have introduced potential bias towards better patient management among prolonged-infusion patients in this study.
Conclusions
This study provides additional PK/PD and clinical outcome data to support the practice of administration of piperacillin/tazobactam and meropenem by prolonged infusion in critically ill patients, particularly for patients with respiratory infections. However, future clinical studies should focus on and test the potential clinical superiority of altered b-lactam dosing approaches in a specific subset of critically ill patients with severe infections who are not receiving renal replacement therapy.
